FIN
Life Sciences
Innovation, patient access and pricing are driving the transformation of the life sciences.
This is a time of enormous disruption in the life sciences sector. New IP being generated and new entrants from the technology industry are accelerating the dawn of personalised medicine.
With a nearly constant stream of capital and emerging technologies, biotech startups have proliferated; investors and Big Pharma are chasing innovations, and drug approvals have hit record levels globally.
Talent acquisition has become a key indicator of future success, with well-funded early stage companies and global pharma companies competing on an increasingly level playing field.
Finland
The European pharmaceuticals market remains in a frustrating position as Europe’s fragmented nature becomes increasingly clear in the wake of the Eurozone crisis.
Ageing populations, growth in emerging markets, and a flood of new technologies should all have spurred growth in the European pharma market. But complex compliance requirements, cash strapped governments, and increasing regulation have reined in pharma’s growth in Europe.
Odgers Berndtson’s global Life Sciences Practice works with pharmaceutical, biotechnology, outsourcing and analytics companies to revitalise their leadership teams and secure growth in Europe and beyond.
People
Insights
The age of Precision Medicine
John Jakenfelds looks at the disruptive forces at work in the life sciences arena and the extraor...
Laying down a biomarker
What are the challenges that researchers face in developing personalised medicine – treatment tha...
What next for Medtech?
As the healthcare sector shifts in response to new economic and social trends, recruitment needs...
